Valuation: VISEN Pharmaceuticals

Market Cap 1.87B 277M 239M 223M 205M 387M 26.33B 392M 2.62B 1.03B 13.17B 1.04B 1.02B 43.64B P/E 2026 *
-18.2x
P/E 2027 * -30.6x
Enterprise Value 1.6B 238M 205M 192M 176M 333M 22.62B 337M 2.25B 883M 11.32B 893M 874M 37.51B EV / Sales 2026 *
23.7x
EV / Sales 2027 * 4.17x
Free-Float
26.93%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 60 2018-11-06
Director of Finance/CFO 42 2025-10-12
Chief Tech/Sci/R&D Officer 54 2020-03-31
Director TitleAgeSince
Director/Board Member 60 2018-11-06
Director/Board Member 44 2021-01-07
Director/Board Member 60 2021-03-31
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 277M
+0.90%+0.21%-0.74%+13.87% 48B
+1.98%+7.31%+430.66%+532.17% 41.13B
+3.44%-2.84%+29.17%+8.81% 37.56B
+1.40%-0.89%+7.63%+61.93% 35.91B
+2.42%+7.27%+14.90%+44.79% 29.86B
-0.16%-4.02% - - 16.12B
+2.20%+2.94%+35.92%+127.15% 16.05B
+1.25%+1.69%+4.72%+18.26% 13.76B
+4.25%-9.28%-0.78%-35.46% 12.1B
Average +1.77%-2.15%+65.18%+96.44% 27.83B
Weighted average by Cap. +1.91%-1.29%+85.86%+120.78%

Financials

2026 *2027 *
Net sales 67.73M 10.05M 8.68M 8.09M 7.45M 14.06M 956M 14.24M 95.13M 37.3M 478M 37.74M 36.91M 1.58B 447M 66.38M 57.34M 53.46M 49.18M 92.84M 6.31B 94.07M 628M 246M 3.16B 249M 244M 10.47B
Net income -99M -14.69M -12.69M -11.83M -10.88M -20.54M -1.4B -20.82M -139M -54.51M -699M -55.16M -53.95M -2.32B -58M -8.61M -7.43M -6.93M -6.38M -12.04M -818M -12.2M -81.46M -31.94M -409M -32.32M -31.61M -1.36B
Net Debt -262M -38.92M -33.62M -31.34M -28.83M -54.43M -3.7B -55.15M -368M -144M -1.85B -146M -143M -6.14B 486K 72.12K 62.3K 58.07K 53.43K 101K 6.86M 102K 683K 268K 3.43M 271K 265K 11.37M
Logo VISEN Pharmaceuticals
Visen Pharmaceuticals is a holding company mainly engaged in developing and commercializing disruptive endocrine therapies. The Company's main products under development include lonapegsomatropin, navepegritide, and palopegteriparatide. The lonapegsomatropin is used to treat growth hormone deficiency in children aged 3 to 17 years old. The navepegritide is a disease repair therapy used to treat children with cartilage dysplasia aged 2 to 10 years old. The palopegteriparatide is a treatment method used to treat adult hypoparathyroidism. The Company is in the late stage of research and development, and its products are close to commercialization.
Employees
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
17.11CNY
Average target price
44.50CNY
Spread / Average Target
+160.05%

Annual profits - Rate of surprise